Chukwunonso Nwabufo
PhD Candidate and CIHR Scholar, Pharmaceutical Sciences, University of Toronto (Biomedical and clinical sciences; Pharmacology and pharmaceutical sciences; Neurology and neuromuscular diseases; Central nervous system; Infectious diseases)
Toronto, Canada
Chukwunonso Nwabufo is a PhD Candidate and CIHR Scholar in pharmaceutical sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto, Canada. He is a multiple award-winning clinical pharmacologist with over six years of experience in drug development across academia and the pharmaceutical industry. Nwabufo contributed to the development of Remdesivir and Lenacapavir approved for the treatment of COVID-19 and HIV respectively, during his tenure at Gilead Sciences. He also contributed to the development of novel compounds under basic science research for the treatment and/or diagnosis of Parkinson’s disease during his MSc program.
Nwabufo’s current research work is focused on deploying pharmacological strategies to improve the clinical efficacy and safety profile of promising COVID-19 drugs. His research work has received the prestigious Canadian Institutes of Health Research Canada Graduate Scholarship Doctoral Award ($105K), and Canadian Institutes of Health Research Canada Graduate Scholarship – Michael Smith Foreign Study Supplements Award ($6K), as well as $121K in funding from the Leslie Dan Faculty of Pharmacy.
Nwabufo has received numerous prestigious awards including the Emerging Academic Scholars Award, and Top 25 Canadian Immigrant Award for his contribution to drug development programs. In general, he has received more than 20 international and national awards and recognitions worth more than C$400K in funding due to academic, research, and leadership accomplishments. Nwabufo is the author of 17 peer-reviewed scientific papers and 11 industry-standard peer-reviewed reports in support of drug development programs.
Nwabufo serves as an editorial board member of Drug Metabolism Reviews and Journal of Applied Bioanalysis. He is an abstract screener for PharmSci360 conference, and 2023/2024 Chair for the Pharmacokinetic, Pharmacodynamic, and Drug Metabolism Community of the American Association of Pharmaceutical Scientists, USA. He is also a member of the Student, Trainee & Early-stage Professional Committee of the American College of Clinical Pharmacology.
Publications
- Unraveling the metabolic fate of potential therapeutic dimer compounds for Parkinson’s disease
- Tandem mass spectrometric analysis of novel caffeine scaffold‐based bifunctional compounds for Parkinson's disease
- Advances in the study of drug metabolism – symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX)
- Pharmacogenomics in the era of next generation sequencing – from byte to bedside
- Relevance of ABC Transporters in Drug Development
- Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
- Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations
- COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples
- Uncovering the Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic and Pulmonary Drug Concentrations Using Physiologically Based Pharmacokinetic Modeling
- SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues
- An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds
- Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds
- Healthcare provider and patient perspectives on the implementation of pharmacogenetic-guided treatment in routine clinical practice
- Biochemical effect of Hibiscus sabdariffa Calyx extracts on the reproductive hormones of male Wistar rat
- Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs
- Potential application of mass spectrometry imaging in pharmacokinetic studies
- Bioanalytical strategies in drug discovery and development
- Uncovering the impact of COVID-19–mediated bidirectional dysregulation of cytochrome P450 3A4 on systemic and pulmonary drug concentrations using physiologically based pharmacokinetic modeling